Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
APLS
APLS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
APLS News
Wall Street Analysts Adjust Ratings
Jan 28 2026
Benzinga
Apellis Pharmaceuticals' Empaveli Approved, Projected $508 Million Sales by 2033
Jan 21 2026
Benzinga
Bank of America Upgrades Apellis Pharmaceuticals to Buy, Highlights Strong Empaveli Launch
Jan 21 2026
seekingalpha
Sobi Secures EU Approval for Aspaveli in Rare Kidney Disorders
Jan 16 2026
seekingalpha
Wall Street Trades Cautiously as CPI Rises 2.7% Amid Weak Earnings Reports
Jan 13 2026
Benzinga
Telsey Raises Five Below Inc Price Target to $240
Jan 13 2026
Benzinga
Gold and Silver Hit Record Highs as Investors Reassess Fed Independence Amid Political Tensions
Jan 12 2026
Benzinga
APLS and SOUN Options Show Significant Volume Surge
Jan 09 2026
NASDAQ.COM
Alphabet Surpasses Apple to Become World's Second Largest Company
Jan 07 2026
Benzinga
Sobi Receives Positive CHMP Opinion for Aspaveli
Dec 12 2025
NASDAQ.COM
Apellis Receives FDA Approval for EMPAVELI to Treat C3G, Achieving 68% Reduction in Proteinuria
Dec 03 2025
Globenewswire
Apellis Receives FDA Approval for EMPAVELI to Treat C3G with 68% Proteinuria Reduction
Dec 03 2025
Newsfilter
This Underrated Biotech May Have Just Demonstrated the Longevity of Its Leading Drug
Nov 12 2025
Benzinga
Brinker International Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Thursday
Nov 06 2025
Benzinga
JP Morgan Keeps Overweight Rating on Apellis Pharmaceuticals, Reduces Price Target to $36
Nov 05 2025
Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for Apellis Pharmaceuticals, Adjusts Price Target to $45
Oct 31 2025
Benzinga
Show More News
